Allergy Therapeutics PLC Allergy hosts Satellite Symposium at EAACI
June 13 2016 - 2:00AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
13 June 2016
13 June 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Allergy Therapeutics hosts Satellite Symposium at EAACI
World-leading allergists present technological advances and
immunotherapy innovations
Allergy Therapeutics (AIM:AGY), the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, announces
today that data was presented in a Satellite Symposium entitled:
"Adjuvants in Allergy: elevating efficacy" at the 35(th) Annual
Congress of the European Academy of Allergy and Clinical Immunology
(EAACI) in Vienna, Austria on 12 June 2016, relating to a number of
the Company's products and technologies.
Three world-leading experts in the field of allergen
immunotherapy and vaccine delivery, Ralph Mösges, Randolph Brehler
and Thomas Kündig, presented information on innovation in
immunotherapy including Allergy Therapeutics' key product Pollinex
Quattro(R). Pollinex Quattro(R)'s specialist technology was
discussed, highlighting the marketed product's ability to reduce
irritation and systemic reactions. Furthermore, Dr Brehler
discussed how the potent depot adjuvant MCT (Micro Crystalline
Tyrosine), initiated by the Company as an alternative to aluminium
in subcutaneous immunotherapy and used in Pollinex Quattro(R) as
well as certain other of the Company's subcutaneous injected
therapies, has an immunomodulating action that augments a shift in
the immune reactions responsible for the symptoms of allergic
rhinitis.
Data on the future role of Virus-Like-Particles (VLP) in
immunotherapy was also presented as a potential new injectable
vaccine immunotherapy technology. Allergy Therapeutics recently
acquired an exclusive VLP technology licence and is conducting a
research project on VLP-based allergy vaccines. The worldwide food
allergy market is worth a potential $8bn and, currently, there is
no established and safe immunotherapy treatments available for
peanut allergy, the first indication the Company intends to
address.
Manuel Llobet, Chief Executive Officer, commented: "As a fully
integrated specialty pharmaceutical company, we are delighted to be
breaking new ground in allergen immunotherapy. Allergy Therapeutics
has the potential to transform allergy treatment with an
established range of diagnostics and specific short-course
aluminium-free immunotherapy vaccines and we are well-placed to
deliver the relief from symptoms of allergy that millions of
patients need."
Satellite Symposium: Adjuvants in Allergy: elevating
efficacy
1) Ultra-short course immunotherapy, Ralph Mösges MD, PhD, MSEE,
University of Cologne (Pulmonology, Allergology and Clinical
Immunology)
2) Adjuvants in immunotherapy, Randolf Brehler MD, University of Münster (Allergology)
3) Future immunotherapy: virus like particles, Thomas Kündig,
University Hospital Zurich (Immunology, Cell Biology and
Pharmacology)
ENDS
For further information please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura
Thornton
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Company sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Company employs c.420 employees and is listed on
the London Stock Exchange (AIM:AGY).
For more information please see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAAKBDBBBKBDAD
(END) Dow Jones Newswires
June 13, 2016 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024